Plain-English translation of NCT07201129 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing whether a medication called can help treat kidney inflammation caused by lupus when added to your regular treatment. Researchers want to know if improves kidney function and what side effects it may cause. Half of participants will receive , and half will receive a placebo (a pill that looks identical but contains no active drug).
Lupus can damage the kidneys, and even with current treatments, some patients continue to have kidney problems. This trial is exploring whether this medication might offer additional protection and healing for kidneys affected by lupus.
You likely qualify if…
You likely don't qualify if…
You will take either the medication or a placebo once daily for about 18 months (76 weeks), alongside your regular lupus medications. You'll visit the clinic every 1 to 3 months for blood tests, urine tests, and checkups to monitor how your kidneys are responding. If you are a woman who can become pregnant, you'll also take monthly pregnancy tests during the trial and for 6 months after it ends.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
United States